{"title":"igg4相关疾病复发的危险因素:系统回顾和荟萃分析","authors":"Fan Yang, Tianqi Wang, Yanying Liu","doi":"10.1007/s10067-025-07641-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Patients with IgG4-related disease (IgG4-RD) suffer high relapse during long-term treatment, but risk factors associated with relapse are not well established. This study aims to review the potential risk factors and integrate relapse rates of observational studies for IgG4-RD.</p><p><strong>Method: </strong>Relevant articles published up to January 28, 2025, were comprehensively and systematically identified from PubMed, EMBASE, and Web of Science databases. A systematic review and meta-analysis was performed to estimate pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence interval (CI).</p><p><strong>Results: </strong>Twenty-four studies comprising 3797 patients were included. Our findings reveal that a history of allergies (OR: 2.97, 95%CI: 2.07-4.25, P < 0.001), multi-organ involvement (HR: 1.60, 95% CI: 1.23-2.09, P = 0.0005), and decreased complement levels (HR: 2.27, 95% CI: 1.04-4.93, P = 0.04) are significantly associated with relapse. Furthermore, the combination of corticosteroids and immunosuppressants significantly reduces relapse rates (HR: 0.25, 95% CI: 0.10-0.62, P = 0.003). The pooled 12-, 24-, and 36-month relapse rates were 17% (95% CI: 0.10-0.24), 26% (95% CI: 0.22-0.31) and 33% (95% CI: 0.26-0.39), respectively.</p><p><strong>Conclusions: </strong>This meta-analysis indicated that a history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. Besides, corticosteroid combined with immunosuppressant therapy could decrease relapse rates. Key Points • A history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. • The combination of corticosteroids and immunosuppressants could reduces relapse rates of IgG4-RD. • The 12-, 24- and 36-month relapse rates of IgG4-RD were 17%, 26% and 33%, respectively.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"4137-4147"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.\",\"authors\":\"Fan Yang, Tianqi Wang, Yanying Liu\",\"doi\":\"10.1007/s10067-025-07641-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Patients with IgG4-related disease (IgG4-RD) suffer high relapse during long-term treatment, but risk factors associated with relapse are not well established. This study aims to review the potential risk factors and integrate relapse rates of observational studies for IgG4-RD.</p><p><strong>Method: </strong>Relevant articles published up to January 28, 2025, were comprehensively and systematically identified from PubMed, EMBASE, and Web of Science databases. A systematic review and meta-analysis was performed to estimate pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence interval (CI).</p><p><strong>Results: </strong>Twenty-four studies comprising 3797 patients were included. Our findings reveal that a history of allergies (OR: 2.97, 95%CI: 2.07-4.25, P < 0.001), multi-organ involvement (HR: 1.60, 95% CI: 1.23-2.09, P = 0.0005), and decreased complement levels (HR: 2.27, 95% CI: 1.04-4.93, P = 0.04) are significantly associated with relapse. Furthermore, the combination of corticosteroids and immunosuppressants significantly reduces relapse rates (HR: 0.25, 95% CI: 0.10-0.62, P = 0.003). The pooled 12-, 24-, and 36-month relapse rates were 17% (95% CI: 0.10-0.24), 26% (95% CI: 0.22-0.31) and 33% (95% CI: 0.26-0.39), respectively.</p><p><strong>Conclusions: </strong>This meta-analysis indicated that a history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. Besides, corticosteroid combined with immunosuppressant therapy could decrease relapse rates. Key Points • A history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. • The combination of corticosteroids and immunosuppressants could reduces relapse rates of IgG4-RD. • The 12-, 24- and 36-month relapse rates of IgG4-RD were 17%, 26% and 33%, respectively.</p>\",\"PeriodicalId\":10482,\"journal\":{\"name\":\"Clinical Rheumatology\",\"volume\":\" \",\"pages\":\"4137-4147\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10067-025-07641-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10067-025-07641-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:igg4相关疾病(IgG4-RD)患者在长期治疗期间复发率高,但与复发相关的危险因素尚未明确。本研究旨在回顾IgG4-RD的潜在危险因素并整合观察性研究的复发率。方法:对PubMed、EMBASE和Web of Science数据库中截至2025年1月28日发表的相关文章进行全面系统的检索。进行系统回顾和荟萃分析以估计合并优势比(ORs)、风险比(hr)和95%置信区间(CI)。结果:纳入24项研究,共3797例患者。我们的研究结果显示过敏史(OR: 2.97, 95%CI: 2.07-4.25, P)。结论:本荟萃分析表明过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。此外,皮质类固醇联合免疫抑制剂治疗可降低复发率。•过敏史、多器官受累和补体水平降低是IgG4-RD复发的危险因素。•糖皮质激素联合免疫抑制剂可降低IgG4-RD的复发率。•IgG4-RD的12、24和36个月复发率分别为17%、26%和33%。
Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.
Objectives: Patients with IgG4-related disease (IgG4-RD) suffer high relapse during long-term treatment, but risk factors associated with relapse are not well established. This study aims to review the potential risk factors and integrate relapse rates of observational studies for IgG4-RD.
Method: Relevant articles published up to January 28, 2025, were comprehensively and systematically identified from PubMed, EMBASE, and Web of Science databases. A systematic review and meta-analysis was performed to estimate pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence interval (CI).
Results: Twenty-four studies comprising 3797 patients were included. Our findings reveal that a history of allergies (OR: 2.97, 95%CI: 2.07-4.25, P < 0.001), multi-organ involvement (HR: 1.60, 95% CI: 1.23-2.09, P = 0.0005), and decreased complement levels (HR: 2.27, 95% CI: 1.04-4.93, P = 0.04) are significantly associated with relapse. Furthermore, the combination of corticosteroids and immunosuppressants significantly reduces relapse rates (HR: 0.25, 95% CI: 0.10-0.62, P = 0.003). The pooled 12-, 24-, and 36-month relapse rates were 17% (95% CI: 0.10-0.24), 26% (95% CI: 0.22-0.31) and 33% (95% CI: 0.26-0.39), respectively.
Conclusions: This meta-analysis indicated that a history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. Besides, corticosteroid combined with immunosuppressant therapy could decrease relapse rates. Key Points • A history of allergy, multi-organ involvement, and decreased complement levels were risk factors for IgG4-RD relapse. • The combination of corticosteroids and immunosuppressants could reduces relapse rates of IgG4-RD. • The 12-, 24- and 36-month relapse rates of IgG4-RD were 17%, 26% and 33%, respectively.
期刊介绍:
Clinical Rheumatology is an international English-language journal devoted to publishing original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level.
The journal succeeds Acta Rheumatologica Belgica, originally founded in 1945 as the official journal of the Belgian Rheumatology Society. Clinical Rheumatology aims to cover all modern trends in clinical and experimental research as well as the management and evaluation of diagnostic and treatment procedures connected with the inflammatory, immunologic, metabolic, genetic and degenerative soft and hard connective tissue diseases.